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Abstract
Several investigations have recently suggested the existence of a correlation between the dose received by the
penile bulb (PB) and the risk of erectile dysfunction (ED) after radical radiotherapy for clinically localized prostate
carcinoma.
A prospective multi-Institute study (DUE-01) was implemented with the aim to assess the predictive parameters of
ED. Previously, an evaluation of inter-observer variations of PB contouring was mandatory in order to quantify its
impact on PB dose-volume parameters by means of a dummy run exercise.
Fifteen observers, from different Institutes, drew the PB on the planning CT images of ten patients; inter-observer
variations were analysed in terms of PB volume variation and cranial/caudal limits. 3DCRT treatment plans were
simulated to evaluate the impact of PB contouring inter-variability on dose-volume statistics parameters. For DVH
analysis the values of PB mean dose and the volume of PB receiving more than 50 Gy and 70 Gy (V50 and V70,
respectively) were considered. Systematic differences from the average values were assessed by the Wilcoxon test.
Seven observers systematically overestimated or underestimated the PB volume with deviations from the average
volumes ranging between -48% and +34% (p < 0.05). The analysis of the cranial and caudal borders showed a
prevalence of random over systematic deviations.
Inter-observer contouring variability strongly impacts on DVH parameters, although standard deviations of inter-
patient differences were larger than inter-observer variations: 14.5 Gy versus 6.8 Gy for mean PB dose, 23.0% versus
11.0% and 16.8% versus 9.3% for V50 and V70 respectively.
In conclusion, despite the large inter-observer variation in contouring PB, a large multi-centric study may have the
possibility to detect a possible correlation between PB % dose-volume parameters and ED. The impact of
contouring uncertainty could be reduced by “a posteriori” contouring from a single observer or by introducing
Magnetic Resonance Imaging (MRI) in the planning procedures and/or in improving the skill of observers through
post-dummy run tutoring of those observers showing large systematic deviations from the mean.
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Background
Erectile dysfunction (ED) is known to be an adverse side-
effect after radiotherapy for prostate cancer [1-14]. The
growing fraction of young patients interested in conser-
ving their potency is leading clinicians and researchers to
devote more attention to this issue, as preservation of
erectile functionality can have a significant impact on the
quality of life of quite a large number of patients likely to
be long survivors after curative radiotherapy for prostate
cancer. From literature there is some evidence of a vascu-
lar ethiopathogenesis of radiation-induced ED, suggesting
that irradiation of the penile bulb (PB), the crura and the
corpora cavernosa could cause post radiotherapy ED
[15-27].
Despite advances in treatment modalities, such as the
use of intensity modulated radiation therapy (IMRT),
leading to better sparing of the erectile structures
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radiotherapy remains a major concern in the Radiother-
apy of prostate cancer.
Although it has been suggested that post radiotherapy
ED may be related to the unnecessary irradiation of
erectile structures, dose constraints have not yet clearly
assessed, as recently reported in several reviews [32-34].
Possible clinical causes of the differences reported in a
number of studies have been associated with the diffi-
culty in assessing ED, the use of anti-impotence drugs
and of hormonal therapy.
Moreover, due to the particular position of the erectile
structures, mainly the penile bulb, technical/dosimetry
uncertainties could play a role: firstly, the position of PB
next to the caudal limit of the irradiation field may intro-
duce additional uncertainty due to the day-by-day set-up
position of the beams. Still more important could be the
uncertainty in delineating PB and other erectile structures,
especially with computed tomography (CT), owing to the
recognised limits of this imaging technique, mainly the
low contrast in the pelvic area. Due to these limitations,
Magnetic Resonance Imaging (MRI) has been proposed as
the most appropriate imaging modality for accurate locali-
sation of the erectile structures [31,35-44].
In a previous study, Perna et al. [31] evaluated the
impact of various imaging modalities and treatment tech-
niques for prostate tumours. The Authors demonstrated
that MRI is superior to CT with regard to soft tissue con-
trast. This technique was consequently found to lead to
better sparing of PB mainly due to a more precise defini-
tion of the prostate apex.
Nevertheless, CT scan is still widely used for prostate
cancer planning, being the standard imaging technique for
most radiotherapy Institutes where access to MRI for
planning is still lacking. Although the well documented
limitation of CT images in the delineation of the penile
bulb could impact on the PB dose volume parameters, no
specific studies have been conducted to date on this
important issue.
In April 2010 a prospective multi-Institute study (Dis-
funzione Urinaria Erettile, DUE-01) was activated after
approval from the ethics committee. The purpose of the
DUE-01 study is to prospectively assess the predictive
parameters of genito-urinary toxicity and ED, including
the possible correlation between ED and PB dose-volume
parameters. In this type of study, involving many Institutes
aiming at evaluating the possible correlation between
normal tissue complication and dose distribution, it is
mandatory to investigate the impact of contouring uncer-
tainties on dose-volume parameters. Accordingly, the first
step of the DUE-01 study was the activation of a dummy
run exercise for the contouring of PB with the aim of: 1)
assessing the impact of contouring uncertainty on PB
dose-volume parameters potentially predictive of ED; 2)
suggesting possible methods/strategies to minimise their
impact; 3) giving individual recommendations to reduce
inter-observer variations in case of operators “significantly
far from the average”.
Methods
CT images of ten prostate patients were randomly
selected for the dummy run exercise. Axial CT images
of the pelvis were acquired with a General Electric Sys-
tem using 110-130 kV and 200-250 mA, 4 mm slice
thickness and 512 × 512 matrix, extending from the
level of the sacrum to below the ischiatic tuberosities.
CT scans were performed on patients with a full urinary
bladder and an empty rectum without any contrast
medium. Patients were placed in the supine position on
a flat couch; legs were slightly flexed with feet immobi-
lized in a foot support combi-fix (Civco Orange City IA,
USA).
Fifteen physicians involved in the treatment of pros-
tate cancer in the different Institutes enrolled in the
DUE-01 study were asked to draw the PB.
Before starting the dummy run, both patients and obser-
vers were anonymised. In order to standardise the PB defi-
nition, all physicians were instructed to adhere strictly to
the following guidelines previously defined by the steering
committee of the study: apart from the definition of well-
known anatomic boundaries (the paired crura laterally, the
corpora spongiosum anteriorly and the levator ani poster-
iorly) [45], because of the low contrast on CT images in
the pelvis area, the anterior border of PB in the more cau-
dal slices was arbitrarily defined as the projection of the
PB anterior border of the most caudal slice, where this
border is more visible. In order to facilitate the observers,
one sample patient with his PB drawn following these
guidelines (see Figure 1) was shown before the contouring
session.
PB contours were drawn using the treatment planning
system (TPS Eclipse-Aria, Varian Inc.) installed at San
Raffaele Hospital - Milan, the coordinating Centre of
the study.
During contouring, every operator was blinded to the
others and optionally used TPS tools such as zoom,
window/contrast level and copying contours, showing
contours on adjacent slices and projected contours on
saggital/coronal view reconstruction.
In order to evaluate the impact of contouring inter-
variability on dose-volume histogram (DVH) parameters,
for each patient, a prostate treatment plan was simulated.
The plan simulations were performed using an 18 MV X-
Ray four field box technique, prescribing a dose of 76 Gy
to the original PTV. Dose distributions were calculated
using the pencil beam model implemented in the TPS,
with modified Batho inhomogeneity correction. Grid size
used for calculation was 2.5 × 2.5 mm.
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volume differences and cranial/caudal limit variations.
For DVH analysis the values of PB mean dose and the
volume of PB receiving more than 50 Gy and 70 Gy
(V50 and V70, respectively) were collected for each
patient and each observer, both as absolute (cc) as well
as relative (%) values. The rationale for the selection of
these DVH parameters was that mean dose and V(50)
as surrogate of a threshold dose for ED, whereas V(70)
was representative of the overlap between the penile
bulb and the target volume.
For each parameter considered, the average difference
between observer and mean values were tested with a
non-parametric Wilcoxon matched-pairs test; p-values
lower than 0.05 were considered statistically significant.
All statistical analyses were performed using SPSS v.17
software.
Finally, the standard deviation of the differences
b e t w e e ne a c ho b s e r v e ra n dt h ea v e r a g ev a l u ew a sc a l c u -
lated for each patient j (SDIO,J)f o ra l lc o n s i d e r e dd o s e -
volume parameters (%V50, %V70; ccV50; ccV70; Mean
PB dose): the global inter-observer variability (SDIO) was
assessed for each parameter as (ΣJSDIO,J)/N, where N is
the number of considered patients (i.e.: N = 10).
For comparison, inter-patient variability was assessed
for each parameter as the SD of the mean value over
the ten considered patients (SDIP), taking the mean
values of all observers for each patient.
Results
Figure 2 shows the mean values and standard deviations
(SD) of the differences between each observer and the
average value of PB volume. In this figure the mean
values and standard deviation of the differences of PB
contour for each patient are also reported.
Seven observers [3-5,7,11,13,14] overestimated or under-
estimated PB volume with significant deviations (p < 0.05)
from the average volumes ranging between -5 cc and +4
cc. Due to the small volume of PB (around 5 - 20 cc) these
differences emphasise a great inter-observers variation
(-48% and +34%). In particular, observer 5 overestimated
PB volume for all patients while, on the contrary, obser-
vers 4 and 7 had a tendency to grossly underestimate PB
volume.
Figure 1 Example of the contouring of the penile bulb, based on the guidelines suggested by the steering committee. The projection
of the PB contour on the more caudal slice from the PB drawn on the more cranial slice is shown by a blue dashed line. This tool was used to
copy the anterior border of the PB contour from the more cranial slice onto the more caudal slice.
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quality of CT images for some patients. An analysis of
inter-observers variability patient-based showed that
patients 2, 6 and 7 are “worse”.
Differences in cranial and caudal limits of PB contours
are shown in figures 3 and 4 respectively. The deviations
were expressed in terms of the average discrepancy and
SD from the slice most frequently drawn from each
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Figure 2 Average deviations and SD between each observer (black) and each patient (grey), and the average value for PB volume.
-4
-3
-2
-1
0
1
2
3
4
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
observer
c
r
a
n
i
a
l
 
s
l
i
c
e
 
d
e
v
i
a
t
i
o
n
s
MODE
min
MAX
Figure 3 Deviations between each observer and the most probable value for the cranial slice of PB.
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Page 4 of 11observer. Maximum values (the more cranial slice) and
minimum values (the most caudal slice) are also indicated
in the figures. Regarding the cranial limit, four observers
[3,9,10,13] showed a systematic (p < 0.05) deviation.
As concerns the caudal border, significant deviations
were found for observers 2 and 3, whose contouring
was approximately 1 slice more caudal, whereas obser-
vers 9 and 15 defined the caudal border more cranially
by, on average, 1 and 2 slices respectively.
An analysis patient-based of the cranial and caudal
borders, although detected some random variations, did
not show significant systematic differences; therefore,
presumably, most deviations were in the lateral and/or
anterior-posterior directions
A plot of the central slice of PB of two patients (one
with the lowest and one with the largest inter-observer
volume variation) is shown in Figure 5.
The impact of inter-observer variations on dose statistic
and DVH parameters was great. The differences in mean
dose of PB among the observers ranged mostly from -20%
to +20%. The differences from mean values were statisti-
cally significant for observers 2, 3, 4, 6, 9 and 12.
A similar trend was evident for DVH parameters: the
differences concerning V50 ranged from -11% to +9% (-2
cc - +2 cc) with p-value statistically significant for 10 out
of 15 observers, whereas, concerning V70, the statistically
significant differences were, for 5 out of 15 observers
[3,4,6,7,12], in the range -8% - +8% (-1 cc - +1 cc).
Figure 6 shows the graphs of PB dose-volume histo-
grams relative to the two patients in figure 5: the first
with the lowest impact of inter-observer variation on
DVH parameters and the second with the greatest
impact of inter-observer variation on DVH parameters.
When considering %DVH parameters, inter-patient
differences were larger than inter-observer differences
(see Figures 7, 8 and 9). SDIP and SDIO were respec-
tively 14.5 Gy and 6.8 Gy for mean PB dose; 23.0% and
11.0% for V50; 16.8% and 9.3% for V70.
On the contrary, when considering absolute (cc) DVH
parameters, the impact of inter-observer variability was
comparable with inter-patient variability: 1.38 cc versus
1.41 cc for V50 and 1.00 cc versus 1.03 cc for V70.
No correlation could be demonstrated between %/cc
DVH variations and PB volume/limit variations.
Discussion
The contouring uncertainty in dose-volume modelling
studies has been generally neglected, or at least under-
reported/under-estimated, despite its potentially impact.
An important general point concerns the need for
clear and simple guidelines for organ delineation; a suc-
cessful application of such guidelines was demonstrated
in the case of the rectum in rectal toxicity dose-volume
relationship studies where a robust anatomically based
definition of the cranial and caudal borders of the rec-
tum guaranteed sufficient reliability of the DVHs col-
lected in a large multi-centric trial [46-48].
The potential impact of PB contouring uncertainty in
the context of prostate cancer radiotherapy presents a
number of special features: in particular, the proximity
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Figure 4 Deviations between each observer and the most probable value for the caudal slice of PB.
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Page 5 of 11of PB to the caudal limit of the PTV suggests that PB
dose-volume parameters are highly sensitive to this
uncertainty. Another specific point concerns the fact
that slight deviations in contouring among different
observers lead to large relative changes in volume and
DVH parameters, due to the relatively small volume
(generally between 5 and 20 cc) of this structure.
The quantification of PB contouring uncertainty is of
primary importance in multi-centric studies dealing with
dose-volume parameters and ED; surprisingly, no data
are available on this point.
The recent start-up of the prospective DUE-01 study
represented a good opportunity to investigate this issue
for the first time; despite the superiority of MRI to CT
in defining PB, it was decided to assess inter-observer
variation in contouring PB on CT images, as this techni-
que still represents the routine practice for most insti-
tutes in Europe, although the use of MRI for prostate
planning is increasingly widespread.
The main result of the current investigation is the
quite large contouring variability, even in the presence
of a much discussed and well-accepted protocol for PB
drawing, including a simplified definition of the anterior
border. Depending on the visibility of PB, which varies
f r o mp a t i e n tt op a t i e n t ,g r e a tu n c e r t a i n t yi nt e r m so f
volume variations could be seen. On the other hand,
although all the observers were highly skilled in prostate
radiotherapy planning, many do not routinely contour
PB in their own Institute; this could partially explain the
high level of uncertainty.
T h ep r a c t i c eo fc o n t o u r i n gP Ba n d / o ro t h e rp e n i l e
structures has yet to be consolidated, as only in recent
years has the problem of ED after radiotherapy for pros-
tate cancer been truly addressed.
T h e r ei se v i d e n c et h a tt h ed o s er e c e i v e db yP Bc o u l d
be predictive of ED, but the literature reports a number
of controversial results [23-27]; on the other hand, the
Roach et al. paper [24] and other results have been very
important in recent years in focusing on the possible
clinical advantage deriving from the sparing of PB and
other erectile structures.
It is quite likely that the increasingly common practice
of contouring PB as an organ-at-risk for potent patients
will rapidly lead to a significant reduction of contouring
variability, such that our results should be considered as
a photograph of the present situation. The increased use
of MRI, too, will likely help in reducing contouring
uncertainty, as demonstrated by evidence that this ima-
ging modality is highly superior to CT in defining PB and
other penile structures.
As a consequence of volume variability, the impact of
contouring uncertainty on dose-volume parameters of PB
was found to be great as well. An important result was
that, without any intervention to reduce it, inter-observer
Figure 5 A plot of the central slice of PB contours drawn by all observers of two patients: one with the lowest inter-observer volume
variation (left side) and one with the largest inter-observer volume variation (right side).
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Page 6 of 11variability of absolute (cc) DVH parameters is as large as
inter-patient variability. This result shows that the dose-
volume relationship for PB would be completely hidden
only due to contouring uncertainty. On the other hand,
inter-patient variability was found to be twofold larger
than inter-observer variability when considering mean PB
dose and % DVH parameters. As an example of the impact
of inter-observer variability, with regard to the constraint
V50 < 50%, our results (1 SD for inter-observer variability
on V50: 11%) suggest that with a V50 value of around 35%
there is still a probability of about 10% that V50 is higher
than the constraint; inversely, if V50 is around 65%, there
is a probability of about 10% that V50 is below our con-
straint. Although our result suggests a significant impact
of contouring variability, in the presence of a large cohort
of patients, as in the DUE-01 study, in which more than
0
10
20
30
40
50
60
70
80
90
100
01 0 2 0 3 0 4 0 5 0 6 0 7 0
Dose (Gy)
v
o
l
u
m
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
01 0 2 0 3 0 4 0 5 0 6 0 7 0
Dose (Gy)
v
o
l
u
m
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
01 0 2 0 3 0 4 0 5 0 6 0 7 0
Dose (Gy)
v
o
l
u
m
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
0
10
20
30
40
50
60
70
80
90
100
01 0 2 0 3 0 4 0 5 0 6 0 7 0
Dose (Gy)
v
o
l
u
m
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
Figure 6 Graphs showing PB dose-volume histograms relative to the two patients in figure 5: the first (top of figure) with the lowest
impact of inter-observer variation on DVH parameters, and the second (bottom of the figure) with the largest impact of inter-
observer variation on DVH parameters.
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Figure 7 Average value and standard deviation of PB dose mean (Gy) for each observer (black) and each patient (grey).
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Figure 8 Average value and standard deviation of V50 (%) for each observer (black) and each patient (grey).
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Page 8 of 11500 patients are expected to be enrolled, the existence of a
dose-volume relationship could be detected. Further inves-
tigation on the expected impact of these uncertainties on
the predictive power of our study is warranted; in any
case, it is clear that % DVH should be used to search for
correlation, while absolute DVH should be ignored.
Attempts to reduce the impact of contouring variabil-
ity are now in progress and include both a re-contour-
ing after an MRI tutorial and specific advice to those
observers for whom the largest systematic deviations
from the average values of PB mean dose and % DVH
were detected.
Another possible solution under discussion is the “a
posteriori” c o n t o u r i n gb yas i n g l eo b s e r v e r ,a sp l a n n i n g
CT information will be collected in the coordinating
centre and analyzed with dedicated research software
(Vodca, Inc).
Conclusion
The dummy run showed very high inter-observer variation
with significant differences in PB contouring among the
various observers, also affecting dose-volume parameters
and consequently the possible relationship with ED. The
high variability should be possibly due to both the limita-
tions of CT images (i.e. the low contrast of the soft tissues
in the pelvis area) and the differing experience among
observers in contouring the erectile structures. The very
large impact on DVH mainly depends on the small PB
volume and its critical position near the caudal border of
the PTV. This study suggests that the reliability of the
quantification of dose-volume effects of penile bulb
defined on CT images may be significantly reduced in
multi-institutional studies. Possible solutions may be the
“a posteriori” c o n t o u r i n gb yas i n g l eo b s e r v e r ,t h ei n t r o -
duction of MRI and/or improving the agreement among
observers after critical review and repetition of the dummy
run procedure.
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